Incivo Finally Approved for Europeans with Hepatitis C | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Four Ways to Beat Hepatitis Fatigue

Back to News Homepage
Next

Could Nitric Oxide Play a Role in Hepatitis C Treatment?

Incivo Finally Approved for Europeans with Hepatitis C

The Editors at Hepatitis Central
September 28, 2011

Print this page

About three months after Victrelis was approved in Europe as the third drug in a triple combination therapy for Hepatitis C, the European Union grants approval to Incivo -Victrelis’s only competition.

J&J’s hep C drug Incivo approved in Europe

Published on 22/09/11

J&J’s potential blockbuster hepatitis C treatment Incivo has been approved in Europe.

Incivo (telaprevir) was approved in combination with peginterferon alfa and ribavirin, having demonstrated significant improvements in cure rates during three phase III studies.

“We are delighted by the European Commission approval of telaprevir and that we can now offer patients a significantly improved treatment option for hepatitis C virus (HCV) compared to the previous standard treatment,” said Ramon Polo, Telaprevir Compound Development team leader.

Incivo, known as Incivek in the US where it was approved in May, will now go head-to-head with another groundbreaking hep C medicine, Merck’s Victrelis.

Continue reading this entire article:
http://www.inpharm.com/news/167734/jj-hepatitis-c-drug-incivo-approved-europe

No Comments - be the first!
Share
Share
Previous

Four Ways to Beat Hepatitis Fatigue

Back to News Homepage
Next

Could Nitric Oxide Play a Role in Hepatitis C Treatment?

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.